| Literature DB >> 17616840 |
Jannique G Z van Uffelen1, Marijke J M Chin A Paw, Marijke Hopman-Rock, Willem van Mechelen.
Abstract
OBJECTIVES: To examine the effect of walking and vitamin B supplementation on quality-of-life (QoL) in community-dwelling adults with mild cognitive impairment.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17616840 PMCID: PMC2039864 DOI: 10.1007/s11136-007-9219-z
Source DB: PubMed Journal: Qual Life Res ISSN: 0962-9343 Impact factor: 4.147
Inclusion and exclusion criteria for participation in the trial
| Operationalization of Petersen criteria for MCI (1–5) and additional inclusion criteria for the RCT (6–12) |
|---|
| 1. Memory complaints (answer yes to question ‘do you have memory complaints’, or at least twice sometimes at cognition scale of Strawbridge [ |
| 2. Objective memory impairment; 10 WLT delayed recall ≤5 + percentage savings ≤ 100 [ |
| 3. Normal general cognitive functioning; TICS ≥ 19 + MMSE ≥ 24 [ |
| 4. Intact daily functioning: no report of disability in activities of daily living on GARS-scale, except on the item ‘taking care of feet and toe nails’ [ |
| 5. Absence of dementia; TICS ≥ 19 + MMSE ≥ 24 |
| 6. Being able to perform moderate intensity physical activity, without making use of walking devices, e.g., a rollator or a walking frame |
| 7. Not using vitamin supplements/vitamin injections/drinks with dose of vitamin B6, B11 or B12 comparable to vitamin supplement given in intervention |
| 8. Not suffering from epilepsy, multiple sclerosis, Parkinson’s disease, kidney disorder requiring haemodialysis, psychiatric impairment |
| 9. Not suffering from depression as measured by the GDS (cut off ≤5) [ |
| 10. Not using medication for rheumatoid arthritis or psoriasis interfering with vitamin supplement |
| 11. No alcohol abuse (men < 21 consumptions a week, women < 15 consumptions a week) |
| 12. Not currently living in a nursing home or on a waiting list for a nursing home |
MCI = Mild Cognitive Impairment, RCT = Randomized Controlled Trial, 10 WLT = 10 Word Learning Test, TICS = Telephone Interview for Cognitive Status, MMSE = Mini Mental State Examination, GARS = Groningen Activity Restriction Scale, GDS = Geriatric Depression Scale
Fig. 1Flow chart. TI = Telephone Interview, WP = Walking Program, PAP = Placebo Activity Program, FA/B12/B6 = Folic Acid, Vitamin B12, Vitamin B6 supplementation, SO = significant other, T6 = follow-up after 6 months, T12= follow-up after 12 months, *reason for exclusion: only baseline data available
Baseline characteristics of participants (n = 152)
| Exercise intervention | Vitamin intervention | |||
|---|---|---|---|---|
| WP ( | PAP ( | FA/B12/B6 ( | Placebo-pill ( | |
| Age (Mean (SD)) | 75 (2.9) | 75 (2.8) | 75 (2.8) | 75 (2.9) |
| Gender (% male) | 48* | 64 | 56 | 55 |
| MMSE (Median (10th–90th ‰)) | 29 (26–30) | 29 (27–30) | 29 (25–30) | 29 (27–30) |
| Education (% low/middle/high) | 61/22/17 | 52/29/19 | 57/26/17 | 55/26/19 |
| Marital status (% living together) | 75 | 68 | 69 | 73 |
| Physical activitya (min/day) (Median (10th–90th ‰)) | 44 (10–155) | 39 (11–120) | 45 (13–155) | 38 (9–111) |
| Vitamin status (% deficient FA/B12/B6)b | 46/8/0 | 48/8/0 | 49/9/0 | 45/7/0 |
| Homocysteine statusc (% hyperhomocysteinemia) | 27 | 23 | 27 | 23 |
| Blood pressure (% hypertension)d | 27* | 14 | 25 | 16 |
| BMI (kg/m2) (Median (10th–90th p‰)) | 26.7 (23.1–31.5) | 26.6 (23.5–32.7) | 26.5 (23.3–32.8) | 26.7 (23.5–31.2) |
| Smoking (% smokers) | 13 | 15 | 17 | 11 |
| Number of self-reported diseases (% 0,1,2)e | 52/42/6 | 69/27/4 | 66/28/6 | 55/41/4 |
WP = Walking Program, PAP = Placebo Activity Program, FA/B12/B6 = Folic Acid, Vitamin B12, Vitamin B6 supplementation, MMSE = Mini Mental State Examination, Education: low = no education, primary education, lower vocational training; intermediate = intermediate level secondary education, intermediate vocational training; high = higher level secondary education, higher vocational training, university training. BMI = Body Mass Index
a ≥3.0 metabolic equivalents
b Cut off points: FA red blood cell <337 nmol/l or FA plasma < 6,3 nmol/l; B12 ≤ 150 pmol/l; B6 < 20 nmol/l
c Homocysteine > 14 mmol/l
d Hypertension = diastole ≥ 90 and systole ≥160
e Cardiovascular disease, chronic obstructive pulmonary disease, diabetes, epilepsy, multiple sclerosis, Parkinson’s disease, psychiatric disease, renal failure requiring dialysis and/or rheumatoid arthritis
* Significantly different from PAP (P < 0.05)
Means (standard deviations) of QoL ratings at baseline and after 6 and 12 months in older adults with MCIa
| WP | PAP | FA/B12/B6 | Placebo | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T0 ( | T6 ( | T12 ( | T0 ( | T6 ( | T12 ( | T0 ( | T6 ( | T12 ( | T0 ( | T6 ( | T12 ( | |
| D-QoL sumscore | 3.5 (0.26) | 3.5 (0.29) | 3.5 (0.27) | 3.5 (0.32) | 3.5 (0.34) | 3.5 (0.34) | 3.5 (0.32) | 3.5 (0.32) | 3.5 (0.33) | 3.4 (0.24) | 3.5 (0.31) | 3.5 (0.27) |
| D-QoL aesthetics | 3.5 (0.63) | 3.5 (0.64) | 3.6 (0.60) | 3.5 (0.70) | 3.5 (0.71) | 3.5 (0.65) | 3.5 (0.64) | 3.5 (0.68) | 3.6 (0.61) | 3.4 (0.68) | 3.5 (0.67) | 3.6 (0.64) |
| D-QoL belonging | 3.7 (0.50) | 3.7 (0.49) | 3.7 (0.44) | 3.8 (0.45) | 3.7 (0.47) | 3.7 (0.46) | 3.8 (0.50) | 3.6 (0.50) | 3.6 (0.48) | 3.7 (0.44) | 3.8 (0.45) | 3.8 (0.40) |
| D-QoL negative affect | 2.7 (0.45) | 2.7 (0.46) | 2.8 (0.50) | 2.7 (0.55) | 2.8 (0.54) | 2.8 (0.52) | 2.7 (0.54) | 2.8 (0.47) | 2.8 (0.53) | 2.7 (0.47) | 2.7 (0.53) | 2.8 (0.49) |
| D-QoL positive affect | 3.8 (0.39) | 3.7 (0.46) | 3.8 (0.40) | 3.8 (0.40) | 3.7 (0.44) | 3.8 (0.43) | 3.8 (0.41) | 3.7 (0.47) | 3.8 (0.44) | 3.8 (0.39) | 3.8 (0.43) | 3.8 (0.39) |
| D-QoL self esteem | 3.6 (0.45) | 3.8 (0.41) | 3.8 (0.40) | 3.7 (0.48) | 3.7 (0.49) | 3.8 (0.48) | 3.8 (0.48)* | 3.8 (0.48) | 3.9 (0.48) | 3.6 (0.43) | 3.7 (0.43) | 3.7 (0.38) |
| SF12-MCS | 54.6 (6.85) | 55.6 (6.40) | 55.3 (4.39) | 54.7 (8.07) | 55.0 (7.34) | 55.3 (6.24) | 55.5 (7.49) | 55.9 (6.91) | 55.8 (4.90) | 53.8 (7.36) | 54.6 (6.86) | 54.8 (5.76) |
| SF12-PCS | 48.2 (7.15) | 48.1 (7.57) | 50.5 (6.13) | 48.7 (7.86) | 48.8 (8.47) | 49.8 (7.04) | 47.9 (8.20) | 47.4 (8.79) | 49.8 (6.68) | 49.1 (6.67) | 49.6 (7.00) | 50.6 (6.49) |
MCI = Mild Cognitive Impairment, WP = Walking Program, PAP = Placebo Activity Program, FA/B12/B6= Folic Acid, Vitamin B12, Vitamin B6 supplementation, D-QoL = Dementia Quality of Life, SF12-MCS = Short Form 12 Mental Component Summary, SF12-PCS = Short Form 12 Physical Component Summary
a Higher rating indicates better QoL
* P < 0.05 (difference between FA/B12/B6 and placebo)
Results of longitudinal multi level analyses on the effect of the WP and FA/B6/B12 supplementation on change in QoL (adjusted model)
| WP versus PAP Beta (95%CI) | FA/B12/B6 versus placebo Beta (95%CI) | ||||
|---|---|---|---|---|---|
| D-QoL sumscore | 0.04 (−0.03;0.10) | 0.25 | −0.06 (−0.12;0.004) | 0.07 | |
| D-QoL aesthetics | 0.06 (−0.07;0.20) | 0.37 | −0.07 (−0.20;0.07) | 0.33 | |
| D-QoL belonging | 0.00 (−0.11;0.11) | 0.96 | −0.18 (−0.29; −0.07) | 0.00 | |
| D-QoL negative affect | −0.02 (−0.12;0.08) | 0.65 | 0.04 (−0.05;0.14) | 0.37 | |
| D-QoL positive affect | 0.04 (−0.04;0.13) | 0.34 | −0.04 (−0.12;0.04) | 0.33 | |
| D-QoL self esteem | 0.08 (−0.02;0.18) | 0.11 | 0.00 (−0.10;0.11) | 0.94 | |
| SF12-PCS | 0.66 (−1.23;2.54) | 0.49 | −0.73 (−2.65;1.19) | 0.45 | |
| SF12-MCS* | Men | −0.82 (−2.24;0.60) | 0.25 | 0.25 (−1.31;1.81) | 0.76 |
| Women | 1.66 (−1.50;4.81) | 0.30 | 1.32 (−1.93;4.56) | 0.42 | |
WP = Walking Program, PAP = Placebo Activity Program, FA/B12/B6= Folic Acid, Vitamin B12, Vitamin B6 supplementation, D-QoL = Dementia Quality of Life, SF12-MCS = Short Form 12 Mental Component Summary, SF12-PCS = Short Form 12 Physical Component Summary
* Interaction WP and gender